A real world study assessing outcomes for ALL patients allocated to receive Tisagenlecleucel nationally, including on an intention to treat (ITT) basis and for those patients who fail CAR T cell therapy
Latest Information Update: 24 Jan 2023
Price :
$35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 24 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition